Investment research report for MMSI

Table of Contents

Executive Summary
Valuation Analysis
Industry and Competitors Analysis
Financial Analysis
Earnings Call Multi-Year Analysis
Financial Statements Multi Year
Insider Trading Analysis
Management Compensation Benchmark Analysis
Proxy Statement Analysis
News Analysis
Technical Indicators Analysis
Financial Statements Annual
Financial Statements Quarterly
Earnings Call Analysis

Executive Summary

Company Description

Merit Medical Systems, Inc. is a leading manufacturer and marketer of single-use medical products for interventional, diagnostic, and therapeutic procedures, primarily in cardiology, radiology, oncology, critical care, and endoscopy. The company operates globally and has a diversified product portfolio across its cardiovascular and endoscopy segments.

Financial Performance and Outlook

Merit Medical has demonstrated strong revenue growth, driven by increased demand across its product lines and strategic acquisitions. The company has focused on improving profitability through operational efficiencies, favorable product mix, and cost management initiatives. Merit maintains a solid balance sheet, generates robust cash flows, and has a manageable debt position, providing financial flexibility for future investments and growth opportunities.

Strategic Initiatives and Growth Drivers

The company is committed to innovation and new product development, with a robust pipeline of new offerings across its segments. Merit has been actively pursuing strategic acquisitions to expand its product portfolio and capabilities, while maintaining a disciplined approach to integration and value creation. The company’s global footprint, particularly in markets like China, presents opportunities for further international expansion.

Competitive Landscape and Risks

Merit Medical operates in the highly competitive medical devices industry, facing competition from larger players like Teleflex, Cooper Companies, and West Pharmaceutical Services. The company’s ability to maintain its competitive position through continued innovation, operational excellence, and strategic acquisitions will be crucial. Additionally, regulatory compliance, legal risks, and potential supply chain disruptions pose challenges that need to be effectively managed.

Back to Table of Contents

Valuation Analysis

PE ratio

  • Low: -171.08886075849927
  • Base: 47.46160372876376
  • High: 266.0120682160268

PB ratio

  • Low: 2.2223153816687655
  • Base: 3.0169999183451623
  • High: 3.811684455021559

FCF Growth

  • Low: -14.42%
  • Med: -3.24%
  • High: 2.07%

Value forecast by FCF

  • Low: 9.36
  • Med: 15.75
  • High: 21.05

The price today for MMSI is $81.34.

Price target for 18 months from now

  • Low: 70.54
  • Med: 71.50
  • High: 72.30

Price target for 4 years from now

  • Low: 52.55
  • Med: 55.10
  • High: 57.22

Price target for 10 years from now

  • Low: 9.36
  • Med: 15.75
  • High: 21.05

The net present value multiplier discounted at 10.22% means the value of the stock is:
– Low: 0.12
– Med: 0.19
– High: 0.26

The upside/downside ratio is 0.03. Our rating is Strong Sell.

Back to Table of Contents

Industry and Competitors Analysis

MMSI’s Industry and Competitors

Based on the information provided, MMSI (Merit Medical Systems, Inc.) operates in the medical devices industry, specifically focused on single-use medical products for interventional, diagnostic, and therapeutic procedures, primarily in cardiology, radiology, oncology, critical care, and endoscopy.

Some of MMSI’s key competitors in this industry include:

  1. Teleflex Incorporated (TFX): A major player in the medical devices industry, offering a wide range of products for vascular access, interventional, anesthesia, surgical, and respiratory applications.

  2. The Cooper Companies, Inc. (COO): A leading manufacturer of contact lenses and medical devices for family and women’s health care.

  3. West Pharmaceutical Services, Inc. (WST): A provider of containment and delivery systems for injectable drugs and healthcare products.

  4. ICU Medical, Inc. (ICUI): A company specializing in infusion therapy and critical care medical devices.

  5. AngioDynamics, Inc. (ANGO): A manufacturer of medical devices for the treatment of peripheral vascular disease, vascular access, and oncology and surgical settings.

  6. AptarGroup, Inc. (ATR): A company that provides dispensing, sealing, and material science solutions for various industries, including the pharmaceutical and healthcare sectors.

  7. Haemonetics Corporation (HAE): A provider of medical products and solutions for plasma collection, blood component collection, and hospital products.

  8. Envista Holdings Corporation (NVST): A company offering dental products, including implant systems, orthodontic products, and dental equipment and consumables.

  9. DENTSPLY SIRONA Inc. (XRAY): A major player in the dental products industry, offering a wide range of technologies, equipment, and consumables for dental professionals.

  10. Alcon Inc. (ALC): A leading eye care company providing surgical equipment, intraocular lenses, and vision care products.

  11. ResMed Inc. (RMD): A company specializing in medical devices and cloud-based software applications for respiratory disorders and sleep apnea.

Based on the financial metrics provided, MMSI appears to be a mid-sized player in the medical devices industry, with a market capitalization of around $4.7 billion and revenue of around $1.25 billion in 2023. Its profitability ratios, such as gross profit, EBITDA, and net income margins, are generally in line with or slightly lower than some of its larger competitors, suggesting a competitive positioning in the industry.

Back to Table of Contents

Chart of Competitors

"Chart of Competitors"

Back to Table of Contents

Financial Analysis

Financial Strength

The company has maintained a healthy current ratio above 2 for most periods, indicating good liquidity position. Debt levels seem reasonable with debt-to-equity ratio mostly below 0.5, though it has increased in recent years. Interest coverage ratio is generally good, suggesting ability to service debt obligations.

Growth Potential

Revenue growth has been inconsistent, with some quarters showing decent growth and others declining. Three-year revenue growth per share has been positive but modest in the 10-25% range for most periods. Operating cash flow growth has been volatile, with some very high and very low growth quarters.

Competitive Advantage

Gross margins have generally been stable around 50%, not indicating a strong competitive advantage. The company operates in the fairly competitive medical device industry, making durable advantages difficult.

Management Quality

Return on equity and assets have been low single-digits for most periods, not suggesting exceptional capital allocation. Operating margins are modest at around 10-15%, leaving room for improvement.

Shareholder Friendliness

The company does not pay dividends currently. Share buybacks do not seem to be a priority based on the data.

Valuation

P/E ratios have varied widely from high 30s to over 100 at times, making valuation assessment difficult. Price/Book has generally been in the 2.5-4x range. Analyst estimates suggest modest revenue/earnings growth expectations over the next few years.

Overall, Merit Medical appears to be a financially stable company operating in a competitive industry. Growth has been uneven, and profitability metrics are decent but leave room for improvement. The company does not seem particularly shareholder-friendly based on the lack of dividends/buybacks. Valuation multiples do not suggest it is significantly over or undervalued compared to historical levels. Stronger revenue growth and margin expansion could improve the investment case.

Back to Table of Contents

Chart of Key Per Share Metrics

"Chart of Key Per Share Metrics"

Back to Table of Contents

Chart of Absolute Metrics

"Chart of Absolute Metrics"

Back to Table of Contents

Earnings Call Multi-Year Analysis

Consistent execution and financial performance

Merit Medical has demonstrated a track record of delivering solid revenue growth, margin expansion, and strong free cash flow generation, even in challenging operating environments. The company’s strategic initiatives, such as the “Foundations for Growth” program, have been instrumental in driving profitability improvements and operational efficiencies.

Diversified product portfolio and innovation pipeline

The company has a well-diversified product portfolio across cardiovascular and endoscopy segments, reducing reliance on any single product line. Merit Medical has a strong focus on innovation, with a robust pipeline of new product launches and a commitment to expanding its clinical evidence portfolio.

Disciplined capital allocation and M&A approach

Merit Medical maintains a strong balance sheet and generates healthy free cash flow, providing flexibility for strategic investments and acquisitions. However, the company has been disciplined in its M&A approach, focusing on deals that align with its strategic priorities and financial criteria.

The company has demonstrated resilience in navigating various headwinds, such as inflationary pressures, supply chain disruptions, and market-specific challenges like volume-based purchasing in China. While these factors may impact near-term performance, Merit Medical’s diversification and operational initiatives have helped mitigate their impact.

Long-term growth and margin targets

Merit Medical has consistently reiterated its commitment to achieving long-term financial targets for revenue growth, operating margins, and free cash flow generation. The company’s transparency and accountability in communicating these targets are positive signals for long-term investors.

Management team and strategic focus

The management team appears aligned and focused on executing the company’s strategic initiatives, such as the “Foundations for Growth” program and the more recent “Continued Growth Initiatives” program. This strategic focus, combined with operational discipline, bodes well for long-term value creation.

Overall, Merit Medical Systems has demonstrated a track record of consistent execution, strategic focus, and financial discipline, positioning the company well for long-term growth and value creation for investors. However, investors should continue to monitor the company’s ability to navigate evolving market dynamics, maintain its innovation pipeline, and capitalize on strategic opportunities.

Back to Table of Contents

Financial Statements Multi Year

Revenue Growth

Merit Medical Systems has demonstrated strong revenue growth over the past few years, driven by increased demand across its cardiovascular and endoscopy segments. However, revenue was negatively impacted by the COVID-19 pandemic in 2020.

Profitability Improvement

The company has been successful in improving its gross margins and profitability through favorable product mix, operational efficiencies, and cost management initiatives. Net income and operating margins improved significantly in recent years, except for 2020 due to the pandemic impact.

Acquisitions and Portfolio Expansion

Merit has been actively pursuing strategic acquisitions to expand its product portfolio and capabilities. While these acquisitions have contributed to revenue growth, successful integration and realizing synergies will be crucial.

Strong Balance Sheet and Cash Flow

The company maintains a solid balance sheet with ample cash reserves and liquidity. It generates strong operating cash flows, providing financial flexibility for investments and acquisitions.

Debt Management

Merit has a manageable debt position, with a mix of fixed and variable interest rates. The company has been able to effectively service its debt obligations.

International Expansion

Merit has a growing international presence, with a significant portion of its revenue coming from international markets, particularly China. Navigating regulatory and geopolitical risks in these markets will be important.

The company faces ongoing regulatory compliance requirements and has been involved in legal proceedings, including settlements with government agencies, which could pose risks and impact financial results.

Research and Development

Merit continues to invest in research and development, focusing on new product development and innovation, which should support future growth.

Overall, Merit Medical Systems has demonstrated resilience and strong financial performance, with a diversified product portfolio, global reach, and a focus on operational excellence. However, the company will need to navigate the challenges posed by the COVID-19 pandemic, regulatory risks, and successfully integrate acquisitions to drive long-term growth and profitability.

Back to Table of Contents

Insider Trading Analysis

The CEO (LAMPROPOULOS FRED P) has consistently held a very large number of shares, over 1 million, and has been actively managing his position through regular stock sales, option exercises, and awards. Other key executives like the CFO (Frost Ronald) and COO (Wright Joseph) have also been granted and exercised a significant number of stock options over time, indicating a focus on long-term incentive compensation. There have been regular stock awards and option grants to a broader group of senior executives and directors, suggesting a company-wide equity compensation program.

Recent Activity

In the past year, there have been several large option exercises and stock sales by the CEO, CFO, and COO, likely driven by the stock’s strong performance. Other executives like the SVP of Operations (Parra Raul Jr.) and Chief Accounting Officer (Peterson Neil) have also been actively managing their positions through option exercises and stock sales. The board and senior leadership team seem to be taking advantage of the stock’s appreciation to diversify their personal holdings, while maintaining substantial ownership stakes.

Implications

The consistent pattern of equity awards, option exercises, and stock sales by the CEO, CFO, COO, and other key executives suggests they are highly incentivized to drive the company’s long-term performance. The recent flurry of selling activity indicates that insiders believe the stock may be fully valued at current levels and are taking some chips off the table. However, the executives still maintain sizable ownership positions, aligning their interests with long-term shareholders. Overall, the insider trading activity points to a well-designed equity compensation program that incentivizes the leadership team to create shareholder value over the long run.

Back to Table of Contents

Management Compensation Benchmark Analysis

Base Salary Portion of Total Compensation

Based on the executive compensation details provided for MMSI, the base salary portion of total compensation for MMSI executives ranges from around 35% to 50%, with the CEO having the lowest base salary portion at around 36%.

Compared to other companies like TFX, COO, and WST, MMSI executives have a higher base salary portion of their total compensation. The average base salary portion for MMSI executives is 60.32%, while the averages for TFX, COO, and WST are 36.18%, 32.91%, and 29.06% respectively.

Alignment with Shareholder Value Creation

This suggests that the executive compensation structure at MMSI is more heavily weighted towards base salary rather than performance-based incentives like bonuses and stock awards. This may not fully align the executives’ interests with long-term shareholder value creation.

To better align executive compensation with long-term shareholder value, MMSI could consider increasing the proportion of performance-based incentives, such as stock awards and incentive plan compensation, relative to base salary. This would tie a larger portion of the executives’ total compensation to the company’s long-term performance and shareholder returns.

Conclusion

In summary, the executive compensation structure at MMSI appears to be more focused on base salary compared to its peers, which may not provide the best alignment with long-term shareholder value creation. Adjusting the compensation mix to include a higher proportion of performance-based incentives could help improve this alignment.

Back to Table of Contents

Proxy Statement Analysis

Executive Compensation Structure

The company has a 2018 Long-Term Incentive Plan that includes equity-based compensation, suggesting a portion of executive pay is tied to long-term performance.

Shareholder Approval

The company is seeking shareholder approval for an amendment to increase the number of shares authorized for issuance under the Long-Term Incentive Plan, as well as a non-binding advisory vote on executive compensation. This indicates an effort to align compensation with shareholder interests.

Governance and Oversight

The Audit Committee’s role in appointing the independent registered public accounting firm is mentioned, which is an important aspect of corporate governance and oversight.

However, the filing does not provide specific details on the performance metrics used in the executive compensation plan or the rationale behind the compensation structure.

Overall, while the information suggests an effort to align executive compensation with long-term value creation through equity incentives and shareholder input, more detailed information on the performance metrics and compensation structure would be needed to fully assess the alignment of incentives with long-term value growth.

Back to Table of Contents

News Analysis

Positive Factors

The company has been consistently launching new products and expanding its product portfolio, which could drive future revenue growth. Some recent launches include the basixSKY inflation device, Siege vascular plug, nsPVA prefilled syringe, Micro ACE micro-access system, expanded Maestro microcatheter line, and Aspira evacuated drainage bottle.

Merit Medical has received several FDA breakthrough device designations for products like the SCOUT surgical guidance system, Embosphere microspheres for knee osteoarthritis treatment, and the WRAPSODY endovascular stent graft system. These designations could accelerate product development and commercialization.

The company has been pursuing growth initiatives and has set financial targets for the 2024-2026 period, indicating optimism about future performance.

Merit Medical’s quarterly earnings and revenues have frequently exceeded Wall Street estimates, reflecting solid execution.

Potential Concerns

The company withdrew its fiscal 2020 guidance due to uncertainties from the COVID-19 pandemic, which could impact near-term performance.

An activist investor, Starboard Value, has taken a stake in the company and pushed for changes, including adding new directors. This could lead to strategic shifts or increased scrutiny on the company’s performance.

There have been some investigations and lawsuits related to potential misleading statements by the company, which could be a distraction or result in legal costs.

Overall, Merit Medical seems to be executing well operationally, with a focus on innovation and new product launches. However, the pandemic’s impact, activist investor involvement, and legal issues introduce some uncertainties. Long-term investors would likely want to monitor how the company navigates these challenges while continuing to drive growth through its product pipeline.

Back to Table of Contents

Technical Indicators Analysis

Next week trading

Based on the recent price movements and technical indicators, the next week’s trading for this company could be volatile. The TEMA (Triple Exponential Moving Average) has been declining, indicating a potential bearish trend in the short-term. The RSI (Relative Strength Index) has been fluctuating between overbought and oversold levels, suggesting a lack of clear directional momentum. Traders should be cautious and monitor the market closely for potential opportunities or risks in the coming week.

Resistance and Support Levels

The current price levels suggest potential resistance around $82-$83 and support around $80-$81. Traders should watch these levels closely as they may act as key support and resistance points in the near-term.

Short Term Investor

For a short-term investor, the current technical indicators present a mixed picture. The declining TEMA and fluctuating RSI suggest a lack of clear directional momentum, making it challenging to identify a strong short-term trend. Short-term investors may consider taking a cautious approach, potentially looking for opportunities to enter or exit positions based on the price action around the identified support and resistance levels.

Long Term Investor

For a long-term investor, the overall technical picture appears more favorable. The 200-day Simple Moving Average (SMA_200) is still trending upwards, indicating a positive long-term outlook. However, the recent decline in the TEMA and the fluctuations in the RSI suggest that the company may be experiencing some short-term volatility. Long-term investors may want to monitor the situation closely and consider adding to their positions on any significant pullbacks, as the long-term trend appears to be intact.

Back to Table of Contents

Chart of Valuation History

"Chart of Valuation History"

Back to Table of Contents

Financial Statements Annual

Financial Statements Annual 2024 Q2

Strong Revenue Growth

Merit Medical Systems reported record annual revenue of $1.15 billion in 2022, up 7.1% compared to 2021. This was driven by strong performance across the company’s cardiovascular and endoscopy segments.

Profitability Improvement

Net income increased to $74.5 million in 2022, up from $48.5 million in 2021, reflecting improved operating leverage and lower legal settlement costs.

Segment Performance

  • Cardiovascular segment revenue grew 7.2% in 2022, led by strong demand for peripheral intervention, cardiac intervention, and OEM products.
  • Endoscopy segment revenue grew 3.9% in 2022, driven by increased sales of Elation Balloon Dilators and EndoMAXX stents.
  • International sales grew 7.4% in 2022 and accounted for 43.5% of total revenue, with China remaining the largest international market.

Operational Efficiency

Gross profit margin was 45.1% in 2022, relatively stable compared to 45.2% in 2021, despite higher freight and logistics costs. The company’s focus on cost discipline and operational improvements helped offset inflationary pressures.

Balance Sheet and Cash Flows

The company generated $114.3 million in operating cash flow in 2022. As of December 31, 2022, Merit had $589.1 million in cash and cash equivalents and $1.98 billion in total debt, with ample liquidity and borrowing capacity under its credit facility.

Acquisitions and Investments

Merit completed several strategic acquisitions and investments in 2022, including the purchase of Restore Endosystems and an increased equity stake in Fluidx Medical Technology.

The company entered into a Corporate Integrity Agreement with the U.S. Department of Justice in 2020 and continues to cooperate with an SEC inquiry related to its China operations. It also settled a shareholder derivative lawsuit in 2022.

Overall, Merit Medical Systems delivered strong financial performance in 2022, demonstrating the resilience of its diversified product portfolio and the effectiveness of its operational initiatives, despite ongoing macroeconomic and supply chain challenges.

Financial Statements Annual 2023 Q2

Strong Revenue Growth

Merit Medical reported record annual revenue of $1.075 billion in 2021, up 11.5% from 2020 and 8% higher than 2019 levels, demonstrating a strong recovery from the COVID-19 pandemic impacts.

Improved Profitability

Gross profit margin increased to 45.2% in 2021 compared to 41.6% in 2020, driven by decreased amortization expense, manufacturing efficiencies, and reduced obsolescence costs. Operating income margin improved to 5.7% in 2021 compared to 0.2% in 2020.

Successful Integration of Acquisitions

Merit has completed several strategic acquisitions in recent years, including KA Medical in 2020, which appear to be integrating well and contributing to the company’s growth. The company continues to actively evaluate acquisition opportunities.

Diversified Product Portfolio and Geographic Reach

Merit has a diverse product portfolio across cardiovascular and endoscopy segments, and a global footprint with 43% of 2021 sales coming from international markets, providing revenue diversification. The company’s largest international market is China.

Strong Balance Sheet and Cash Flow

Merit generated $147 million in operating cash flow in 2021 and ended the year with $678 million in cash and cash equivalents. The company has manageable debt levels with a revolving credit facility providing ample liquidity.

Ongoing Investments in R&D and Operational Improvements

Merit continues to invest significantly in new product development and clinical trials, as well as initiatives to optimize operations, reduce costs, and streamline its product portfolio – all of which should support future growth.

The company faces ongoing regulatory compliance requirements and legal proceedings, including a recent $18.7 million settlement with the Department of Justice, which could pose risks and impact financial results.

Overall, Merit Medical appears to be executing well on its strategic priorities, delivering strong financial performance, and positioning itself for continued growth, though regulatory and legal matters remain areas of potential concern for long-term investors.

Financial Statements Annual 2022 Q2

Impact of COVID-19 Pandemic

The COVID-19 pandemic had a significant negative impact on Merit’s business in 2020, with sales declining 3.1% compared to 2019. The most significant impact was in Q2 2020, with sales down 14.5% year-over-year. In response, Merit implemented cost reduction measures including headcount reductions, temporary salary reductions, and deferring or rationalizing capital spending.

Financial Performance

Net sales in 2020 were $963.9 million, down from $994.9 million in 2019. Gross profit margin declined to 41.6% in 2020 from 43.5% in 2019, primarily due to changes in product mix and increased obsolescence expense. Net income in 2020 was a loss of $9.8 million, compared to net income of $5.5 million in 2019. This was largely due to the $187 million legal settlement with the DOJ and $365 million in impairment charges.

Segment Performance

The cardiovascular segment, Merit’s largest, saw sales decline 2.8% to $934.2 million in 2020. Operating income for this segment declined from $25.8 million in 2019 to a loss of $7.0 million in 2020. The endoscopy segment sales declined 12.4% to $29.7 million in 2020. However, operating income for this segment improved from a loss of $10.3 million in 2019 to a gain of $5.5 million in 2020.

International Sales

International sales declined 13% to $413.8 million in 2020, representing 42.9% of total sales, down from 42.1% in 2019. China remained Merit’s largest international market, with sales of $113.2 million in 2020, essentially flat compared to 2019.

Liquidity and Capital Resources

Merit generated $165.3 million in cash from operations in 2020, up from $77.8 million in 2019. As of December 31, 2020, Merit had $56.9 million in cash and $351.2 million in long-term debt outstanding.

In summary, the COVID-19 pandemic had a significant negative impact on Merit’s financial performance in 2020, leading to declines in sales, profitability, and cash flow. The company took actions to reduce costs, but still recorded substantial impairment charges and a major legal settlement. Looking ahead, Merit will need to navigate the ongoing effects of the pandemic on its business.

Back to Table of Contents

Financial Statements Quarterly

Financial Statements Quarterly 2024 Q2

Revenue Growth

The company reported strong revenue growth of 8.7% year-over-year, driven by increased demand across its cardiovascular and endoscopy segments. This indicates the company is maintaining its market position and expanding its customer base.

Gross Margin Improvement

Gross profit as a percentage of sales increased to 46.9% from 46.5% in the prior year period. This suggests the company is effectively managing its costs and product mix to improve profitability.

Operational Efficiency

The company was able to leverage its operating expenses, with selling, general and administrative expenses decreasing as a percentage of sales. This points to ongoing efforts to streamline operations and drive productivity.

Strong Cash Flow and Liquidity

The company generated $36.2 million in operating cash flow and ended the quarter with $581.9 million in cash and cash equivalents. This provides ample financial flexibility to fund growth initiatives, make strategic investments, and weather potential economic headwinds.

Debt Management

The company has $872.7 million in total debt, with $860.3 million in long-term debt. While the debt load is significant, the company appears to be managing it effectively, as evidenced by its ability to make scheduled repayments and maintain compliance with its debt covenants.

Acquisition Integration

The company completed several acquisitions during the period, including the purchase of assets from AngioDynamics and Bluegrass Vascular Technologies. The successful integration of these acquisitions and the realization of expected synergies will be important for driving future growth and profitability.

Contingent Consideration

The company has recorded contingent consideration liabilities related to its past acquisitions, which are subject to periodic remeasurement. The changes in the fair value of these liabilities can impact the company’s operating results and should be monitored by investors.

Overall, the financial statements indicate that Merit Medical Systems is executing well on its strategic initiatives, maintaining a strong market position, and generating solid financial performance. The company’s focus on operational efficiency, cash flow generation, and prudent capital allocation should be appealing to long-term investors.

Financial Statements Quarterly 2024 Q1

Revenue Growth

Total revenue increased 9.8% in Q3 2023 and 8.8% in the first 9 months of 2023 compared to the prior year periods. This was driven by strong performance across the cardiovascular and endoscopy segments.

The cardiovascular segment saw revenue growth of 9.7% in Q3 and 8.7% in the first 9 months, with particular strength in peripheral intervention, cardiac intervention, and OEM products.

The endoscopy segment grew revenue 11.2% in Q3 and 10.0% in the first 9 months, driven by increased sales of products like the EndoMAXX stent and Elation Pulmonary Balloon Dilator.

Profitability Improvement

Gross profit margin increased to 45.1% in Q3 2023 from 44.8% in Q3 2022, and to 46.5% in the first 9 months of 2023 from 44.8% in the prior year period.

This was driven by the higher sales volume, favorable changes in product mix and standard costs, and lower freight expenses as a percentage of sales.

Operating income increased 88.3% in Q3 2023 and 58.0% in the first 9 months of 2023 compared to the prior year periods, due to the higher sales and gross margins.

Acquisition Activity

In 2023, Merit completed the acquisitions of assets from AngioDynamics, Bluegrass Vascular Technologies, and Advanced Radiation Therapy, expanding its product portfolio and capabilities.

These acquisitions required significant cash outflows, with $138 million spent on acquisitions in the first 9 months of 2023.

The integrations of these acquired assets are still in early stages, presenting both opportunities and risks that Merit will need to manage.

Balance Sheet and Cash Flows

Merit ended Q3 2023 with $607 million in cash, cash equivalents and restricted cash, and $558 million in available borrowing capacity.

Operating cash flow was $829 million in the first 9 months of 2023, funding the acquisition activity and capital expenditures.

Debt increased to $891 million as of Q3 2023 to finance the recent acquisitions, with a mix of fixed and variable interest rates.

Overall, Merit delivered strong revenue and profitability growth in 2023 so far, while also investing significantly in expanding its product portfolio through acquisitions. Effectively integrating these acquisitions will be a key focus going forward.

Financial Statements Quarterly 2023 Q4

Revenue Growth

Total revenue for the 3-month period ended June 30, 2023 increased 8.5% to $320.1 million compared to the prior year period. Total revenue for the 6-month period ended June 30, 2023 increased 8.3% to $617.6 million compared to the prior year period. The revenue growth was driven by strong performance across the Cardiovascular segment, with increases in Peripheral Intervention (13.5%), Cardiac Intervention (4.7%), Custom Procedural Solutions (0.6%), and OEM (13.9%) product categories. The Endoscopy segment also saw revenue growth of 5.7% in the 3-month period and 9.4% in the 6-month period.

Gross Margin Expansion

Gross profit as a percentage of sales increased to 47.7% in the 3-month period, up from 45.8% in the prior year period. Gross profit as a percentage of sales increased to 47.1% in the 6-month period, up from 44.9% in the prior year period. The improvement in gross margins was driven by favorable product mix, manufacturing efficiencies, and lower freight costs.

Profitability Improvement

Net income for the 3-month period was $20.2 million, or $0.35 per diluted share, compared to $15.3 million, or $0.27 per diluted share, in the prior year period. Net income for the 6-month period was $40.9 million, or $0.70 per diluted share, compared to $25.8 million, or $0.45 per diluted share, in the prior year period. The increase in profitability was driven by higher sales, improved gross margins, and lower acquisition-related costs.

Acquisitions and Investments

The company completed the acquisitions of a portfolio of dialysis catheter products and the BioSentry Biopsy Tract Sealant System from AngioDynamics, and the Surfacer InsideOut Access Catheter System from Bluegrass Vascular Technologies. The company also invested $40 million to acquire a stake in Solo Pace Inc., the owner and developer of a temporary external pulse generator and grounding pad.

Balance Sheet and Cash Flows

As of June 30, 2023, the company had $742 million in cash, cash equivalents, and restricted cash, and $507 million in available borrowing capacity. Cash provided by operating activities was $31.8 million in the 6-month period, compared to $50.8 million in the prior year period, primarily due to increased inventory investment. Cash used in investing activities was $157.8 million, primarily for the acquisitions completed during the period.

Overall, Merit Medical Systems delivered strong financial performance in the first half of 2023, driven by revenue growth, margin expansion, and strategic investments, despite some headwinds in working capital and cash flows.

Financial Statements Quarterly 2023 Q3

Revenue Growth

The company reported strong revenue growth of 8.0% year-over-year, driven by increased sales across its cardiovascular and endoscopy segments. This indicates the company is maintaining its market position and demand for its products.

Gross Margin Expansion

Gross profit margin increased from 43.9% to 46.5%, reflecting favorable product mix, operational efficiencies, and lower freight/distribution costs. This suggests the company is effectively managing its costs and improving profitability.

Increased R&D Investment

Research and development expenses increased 22.6% year-over-year, as the company is investing in new product development and regulatory compliance, particularly related to the EU Medical Device Regulation. This indicates the company is focused on innovation and expanding its product portfolio.

Strong Cash Flow and Liquidity

The company generated $145 million in operating cash flow and had $601 million in cash and cash equivalents as of March 31, 2023. This provides ample liquidity to fund operations, capital expenditures, and potential acquisitions.

Manageable Debt Position

The company has $197.7 million in total debt, with $186.4 million in the long-term portion. The debt is primarily tied to the company’s revolving credit facility, which provides flexibility and access to additional capital as needed.

Contingent Consideration Liabilities

The company has $16.0 million in contingent consideration liabilities related to prior acquisitions. While this represents a potential future cash outflow, the company appears to be managing these obligations effectively.

Overall, the financial statements indicate Merit Medical is executing well, driving revenue growth, improving profitability, investing in R&D, and maintaining a strong balance sheet and liquidity position – all positive signs for long-term investors.

Back to Table of Contents

Earnings Call Analysis

Earnings Call Analysis 2024 Q2

Strong financial performance

Merit Medical reported solid revenue growth of 8.7% year-over-year on a GAAP basis and 9.3% on a constant currency basis in Q1 2024. This exceeded the high end of the company’s guidance range. The company also delivered strong profitability with non-GAAP gross profit and operating profit growth of 10% and 16% respectively, leading to margin expansion.

Diversified product portfolio and pipeline

The company highlighted several new product introductions across its Cardiovascular and Endoscopy segments, demonstrating a robust pipeline and commitment to innovation. This includes the SCOUT MD Surgical Guidance System, Micro ACE Advanced Micro-Access System, and progress on the WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal study.

Cautious guidance and execution

While the company had a strong start to the year, management maintained its full-year guidance and did not raise it after the first quarter. This suggests a prudent and disciplined approach to managing expectations. The company also provided transparency on factors like the impact of SKU rationalization and China volume-based purchasing that could affect future performance.

Focus on profitability and cash flow

The company emphasized its efforts to drive gross margin expansion through initiatives like product line transfers and pricing actions. It also highlighted strong free cash flow generation in Q1, which it expects to continue throughout the year.

Potential M&A opportunities

The company indicated it continues to evaluate M&A opportunities, but will be selective and ensure any acquisitions align with its long-term strategic objectives.

Overall, the key insights suggest Merit Medical is a well-managed company with a diversified product portfolio, strong financial performance, and a disciplined approach to execution and capital allocation. The long-term investor should closely monitor the company’s progress on new product introductions, profitability improvements, and any strategic M&A activities.

Earnings Call Analysis 2024 Q1

Consistent Execution and Growth

Merit Medical has delivered strong financial performance, with nearly 10% constant currency revenue growth, 120 basis points of non-GAAP operating margin expansion, and over $110 million in free cash flow generation in 2023. This was driven by the successful execution of their Foundations for Growth (FFG) program.

Continued Growth Initiatives (CGI) Program

Merit has introduced a new three-year CGI program, building on the success of FFG. The key objectives are to maintain above-market profitable growth, significantly improve non-GAAP operating margins, and strengthen the company’s culture and employee engagement.

Balanced Growth Outlook

The CGI program targets a revenue CAGR of at least 5-7% and non-GAAP operating margins of 20-22% by 2026. This growth is expected to be driven by existing products, with new product launches providing potential upside.

Margin Expansion Drivers

Merit expects to drive margin expansion through a combination of gross margin improvements (e.g., network consolidation, lean manufacturing) and operating expense leverage, rather than relying solely on one lever.

Prudent Capital Allocation

Merit has a disciplined approach to M&A, evaluating opportunities that fit their strategy and financial profile. The recent convertible note offering has provided additional financial flexibility.

China Headwinds

Merit expects continued headwinds in China due to volume-based purchasing, though they anticipate unit volume growth in the market.

Overall, Merit Medical appears to be executing well on its strategic initiatives and positioning the company for long-term, sustainable growth and profitability improvement. The management team’s transparency and commitment to accountability are positive signals for long-term investors.

Earnings Call Analysis 2023 Q4

Execution on “Foundations for Growth” Program

Merit Medical has executed well on its “Foundations for Growth” program, delivering strong revenue growth, margin expansion, and free cash flow generation. The company expects to meet or exceed its 3-year targets set in this program.

Guidance and Future Targets

The company is focused on completing the Foundations for Growth program in 2023 and is not providing detailed guidance for 2024 and beyond yet. However, they indicate they will introduce new 3-year financial targets on the Q4 2023 call.

WRAPSODY Product Pipeline

The WRAPSODY product is a key pipeline opportunity, but the company is waiting to provide more details on the commercial opportunity and reimbursement until after the clinical trial data is filed with the FDA, expected in mid-2024.

Recent Acquisitions Integration

The company has made progress integrating the recent acquisitions, which are performing better than expected so far. This provides an additional growth avenue.

China Market Headwinds

China remains a headwind, with volume-based purchasing tenders impacting sales, but the company has this factored into its guidance.

Impact of Weight Loss Drugs

The company is closely monitoring potential impacts from weight loss drugs (GLP-1s) on its business, but does not see an immediate material impact based on feedback from physician advisors.

Balance Sheet and M&A Flexibility

The company maintains a strong balance sheet and free cash flow generation, providing flexibility for further M&A if the right opportunities arise, though the team remains disciplined on valuations given the current environment.

Overall, the company appears to be executing well on its strategic initiatives and positioning itself for continued long-term growth, while remaining cautious on providing detailed forward guidance until the current program is completed.

Earnings Call Analysis 2023 Q3

Diversification and strategic acquisitions

Merit is strategically expanding its product portfolio through acquisitions, such as the recent deals with AngioDynamics and Bluegrass Vascular. This diversifies the company’s offerings and strengthens its position in key markets like dialysis and biopsy.

Operational efficiency and margin expansion

Merit’s Foundations for Growth program is driving impressive improvements in gross and operating margins, despite inflationary pressures. The company has been able to leverage pricing, supply chain optimization, and fixed cost leverage to expand profitability.

Cautious international outlook

While the U.S. market remains strong, Merit is more cautious on international growth, particularly in China and Russia, due to factors like volume-based purchasing programs and sanctions. This could weigh on overall revenue growth in the second half of 2023.

Consistent free cash flow generation

Despite headwinds, Merit has demonstrated the ability to generate robust free cash flow, which management is committed to maintaining. This provides financial flexibility for strategic investments and shareholder returns.

Potential risks and uncertainties

Investors should be aware of potential risks, such as supply chain challenges, regulatory changes in China, and the integration of acquired assets. The company’s ability to navigate these issues will be crucial for long-term success.

Overall, Merit’s diversification efforts, operational excellence, and focus on free cash flow generation are positive signs for long-term investors. However, the company’s international exposure and integration of new assets warrant close monitoring.

Earnings Call Analysis 2023 Q2

Operational Execution and Reliability

Merit Medical’s strong revenue growth and margin expansion in Q1 was driven by its ability to reliably deliver products to customers, leveraging its vertical integration and operational efficiency initiatives.

Diversified Growth Drivers

The company saw broad-based strength across its product categories, with peripheral intervention, OEM, and endoscopy segments all contributing to the upside. This diversification reduces reliance on any single product line.

Prudent Investment Approach

While the company is seeing strong profitability, it is taking a balanced approach, reinvesting in growth initiatives like sales meetings and trade shows, rather than solely focusing on margin expansion.

Cautious Guidance

Despite the Q1 outperformance, the company is maintaining a cautious stance on the full-year outlook, noting they want to see the strong trends continue before getting too far ahead of themselves.

Acquisition Strategy

The company is being selective and patient on potential acquisitions, focusing on assets that fit its sales channels and strategic priorities, rather than chasing deals at high valuations.

Succession Planning

The company plans to announce a formal succession plan in the second half of 2023, providing clarity on the long-term leadership transition, which is a key consideration for long-term investors.

Overall, the call highlights Merit Medical’s operational discipline, diversified growth drivers, and prudent approach to both investments and M&A – all positive signs for long-term investors.

Earnings Call Analysis 2023 Q1

Execution and Profitability Improvement

Merit Medical has delivered strong revenue growth, margin expansion, and free cash flow generation in 2022, demonstrating solid execution of its Foundations for Growth (FFG) program. The company remains committed to the financial targets outlined under FFG through 2023.

New Product Development and Clinical Evidence

The company has made progress on new product launches, regulatory clearances, and expanding its clinical evidence portfolio, which are important strategic initiatives.

Pricing and Cost Management

Pricing is a key focus area under FFG, with the company implementing initiatives to improve pricing discipline and pass through inflationary costs. However, the company did not provide specific quantification of the pricing impact.

Geographic Performance

The company saw strong international growth, particularly in the EMEA region, offsetting some headwinds in China due to volume-based purchasing. The company expects the international markets to continue contributing to growth in 2023.

Cautious M&A Approach

The company has a strong balance sheet but is taking a patient and disciplined approach to M&A, focusing on finding the right strategic fit that aligns with its FFG program rather than pursuing deals aggressively.

2023 Guidance

The company provided detailed 2023 financial guidance, including expectations for revenue growth, margin expansion, and free cash flow generation. However, the first quarter guidance suggests some near-term macro uncertainty.

Overall, the company appears to be executing well on its strategic initiatives, but investors should closely monitor the company’s ability to sustain its profitability improvements and navigate the evolving global environment.

Earnings Call Analysis 2022 Q4

Strong Execution and Resilience

Merit Medical has demonstrated strong execution and resilience despite a challenging macroeconomic environment. The company has been able to navigate supply chain disruptions, inflationary pressures, and currency headwinds to deliver better-than-expected revenue growth and profitability.

Vertical Integration and Expense Management

The company’s vertical integration and prudent expense management have been critical factors in offsetting inflationary pressures on raw materials, freight, and logistics. This has allowed Merit to maintain healthy margins and cash flow generation.

New Product Development and Commercialization

Merit’s new product development and commercialization efforts have been a key driver of growth, with several new product launches in the third quarter across its cardiovascular and endoscopy segments. This demonstrates the company’s commitment to innovation and expanding its product portfolio.

While the company faces some ongoing supply chain and staffing challenges, it appears to be managing these issues well and maintaining strong customer demand. The impact of potential macroeconomic headwinds, such as a recession or resurgence of COVID-19, remains a concern, but Merit’s diversified product portfolio and historical resilience suggest it may be able to weather these challenges.

Foundations for Growth Program

Merit’s focus on its “Foundations for Growth” program, which includes initiatives around pricing, operational efficiency, and strategic investments, appears to be paying off and positioning the company for continued long-term success. The company’s commitment to these strategic priorities and financial targets is a positive signal for investors.

Financial Flexibility

The company’s strong cash flow generation and healthy balance sheet provide flexibility for potential strategic acquisitions or investments, though the management team remains disciplined and focused on executing its existing plan.

Overall, Merit Medical’s performance and management’s commentary suggest the company is well-positioned to navigate the current environment and continue delivering value for long-term investors.

Earnings Call Analysis 2022 Q3

Strong Execution and Momentum

The company has delivered better-than-expected revenue and profitability results, demonstrating strong execution by the team. There is a clear focus and momentum behind the company’s Foundations for Growth strategic initiatives.

Inflationary Pressures

The company is facing inflationary headwinds, particularly in raw materials and freight/logistics costs. This has led to a reduction in the gross margin guidance for 2022, though the company believes it can still achieve its long-term margin targets.

Diversified Growth Drivers

The company is seeing broad-based growth across its product categories and geographic regions, with particular strength in the U.S. and international markets like EMEA. This diversification reduces reliance on any single driver.

Transitory Headwinds

The company is managing through some temporary business disruptions, particularly in its endoscopy segment due to issues with a third-party contract manufacturer. This is expected to be resolved in the coming quarters.

Commitment to Long-Term Targets

Despite the near-term challenges, the company remains committed to its Foundations for Growth program and the associated 3-year financial targets for revenue growth, operating margins, and free cash flow generation. The management team and Board appear aligned on these goals.

Disciplined M&A Approach

The company is actively evaluating M&A opportunities but remains disciplined, with a focus on deals that fit its strategic and financial criteria and do not disrupt the momentum of the Foundations for Growth initiatives.

Overall, the company appears to be executing well and making progress on its strategic initiatives, though it faces some near-term inflationary and operational headwinds. The long-term focus and commitment of the management team is a positive sign for long-term investors.

Earnings Call Analysis 2022 Q2

Merit Medical is executing well despite a challenging operating environment

Merit Medical is executing well despite a challenging operating environment, delivering better than expected revenue growth in Q1. This was driven by strong demand, particularly in the U.S. and international markets.

Foundations for Growth program is helping to offset inflationary cost pressures

The company is making good progress on its “Foundations for Growth” program, which is helping to offset inflationary cost pressures in areas like logistics, labor, and raw materials. This program is expected to continue driving value creation.

Management taking a patient approach on guidance

While the company did not raise guidance, management indicated they are taking a patient approach, preferring to wait until after Q2 to potentially revise guidance. This suggests they want to see how the operating environment evolves before making changes.

Disruption in endoscopy business expected to be transitory

The company is seeing some disruption in its endoscopy business due to issues with a third-party manufacturer, but expects this to be transitory and for growth to normalize in the second half of 2022.

Disciplined approach to long-term value creation

Merit is focused on driving long-term shareholder value through the Foundations for Growth program rather than commenting on potential M&A or private market interest. The company seems disciplined in its approach.

Confidence in navigating inflationary and supply chain challenges

Management expressed confidence in their ability to navigate the current inflationary and supply chain challenges, leveraging initiatives like pricing actions and inventory management to offset headwinds. The company’s strong free cash flow generation is also a positive.

Overall, Merit appears to be executing well operationally and taking a prudent, long-term approach despite near-term challenges. The Foundations for Growth program seems to be a key driver of the company’s strategy.

Earnings Call Analysis 2022 Q1

Merit Medical’s Strong Execution and Commitment to Financial Targets

Merit Medical is executing well and delivering strong performance despite the challenging operating environment, demonstrating the team’s ability to remain focused on strategic initiatives.

The company’s Foundations for Growth (FFG) program is helping to offset inflationary cost pressures and drive value creation across areas like SKU optimization, network consolidation, and manufacturing initiatives. The benefits from FFG are expected to continue.

The company remains committed to the financial targets outlined in the FFG program, including constant currency organic revenue growth of at least 5% CAGR, non-GAAP operating margins of at least 18%, and cumulative free cash flow of over $300 million by the end of 2023.

Disciplined Approach to M&A

While the company is open to M&A opportunities, it is maintaining discipline and will only pursue deals that are consistent with or exceed the FFG program expectations. The strong free cash flow generation provides flexibility.

The company is closely monitoring global supply chain disruptions but has avoided material business impacts so far. However, this remains an area of focus going forward.

Guidance and Outlook

The guidance for 2022 assumes some continued COVID-related headwinds, particularly in the first quarter, as well as inflationary pressures of around 120 basis points on gross margins. The company expects a gradual improvement in the operating environment over the first half of 2022.

The China business performed better than expected in Q4 2021 due to pent-up demand ahead of anticipated volume-based purchasing tenders, though the timing and impact of these tenders remains uncertain.

Earnings Call Analysis 2021 Q4

Profitability Improvement

Merit Medical has delivered impressive profitability improvement, margin expansion, and free cash flow generation. Over the first 9 months of 2021, they have expanded non-GAAP gross margins by 220 basis points and increased non-GAAP operating margins by 250 basis points year-over-year.

Strong Execution

Despite a challenging operating environment, Merit was able to deliver revenue results that exceeded their guidance, demonstrating strong execution from the team. They are confident in their 2021 guidance which calls for 9-10% total revenue growth on a constant currency basis.

Foundations for Growth Program

Merit’s multi-year Foundations for Growth program is helping to offset inflationary cost pressures through initiatives like SKU rationalization, product line transfers, and manufacturing efficiency improvements. This program is a key driver of their margin expansion.

China Dynamics

The timing of tenders in China has been delayed, providing a temporary benefit to Merit’s sales in Q3. However, they expect the tender-related pricing pressure to impact them in the first half of 2022. Merit remains confident in the long-term growth opportunity in China.

Supply Chain Challenges

Merit has faced some supply chain disruptions, particularly impacting their endo max product line. However, they expect these issues to be resolved by the end of 2021.

Debt Reduction and Capital Allocation

Merit has used its strong free cash flow to pay down $72.6 million in debt over the first 9 months of 2021. They are focused on debt reduction and strategic investments to support their Foundations for Growth initiatives, rather than pursuing acquisitions at this time.

Overall, the key message is that Merit is executing well on its strategic initiatives to drive profitability and cash flow, despite the challenging operating environment. The long-term investor should focus on the company’s progress in margin expansion, free cash flow generation, and its ability to navigate supply chain and inflationary pressures.

Earnings Call Analysis 2021 Q3

Merit Medical’s Strategic Execution and Growth Outlook

Merit Medical is focused on innovation and new product development, which is a key part of their growth strategy. They have a robust pipeline of new products across their cardiovascular and endoscopy segments.

The company is closely managing its working capital and cash flow, which has resulted in strong free cash flow generation. This provides flexibility for potential M&A or other strategic initiatives.

There are some near-term headwinds impacting the 2021 revenue guidance, including the exit of certain non-core businesses in 2020 and the expected pricing pressure from tenders in China. However, the company remains confident in its mid-to-high single digit constant currency revenue growth outlook for 2021, excluding these one-time impacts.

The WRAPSODY product launch in Europe is progressing, though access to hospitals remains limited due to the ongoing COVID-19 situation. The company is also initiating a clinical trial for WRAPSODY in the U.S. which will be an important milestone.

The company is focused on operational efficiency and cost management as part of its “Foundations for Growth” initiative. This has led to improved profitability and cash flow, which the company plans to sustain going forward.

Management seems cautious about raising full-year guidance despite the strong Q1 performance, likely due to the lingering uncertainty around the China tenders and the broader macroeconomic environment. However, they remain confident in the underlying business trends.

Overall, Merit Medical appears to be executing well on its strategic initiatives, with a focus on innovation, operational efficiency, and financial discipline. The long-term investor should watch for continued progress on new product launches, margin expansion, and the company’s ability to navigate the evolving market dynamics.

Back to Table of Contents

The information provided on this blog is for informational purposes only and should not be considered as financial advice. You should consult with a qualified financial professional before making any investment decisions. Past performance is not indicative of future results. Investing involves risk, including the potential loss of principal.